First is static barriers which include different layers of cornea, sclera and retina including blood aqueous and blood-retinal barriers (Gaudana et al., 2010). [...]is dynamic barriers, this included choroidal and cobnjunctival blood flow, lymphatic clearance and tear dilution. Differences in manufacturing or the formulation design leads to variation in particle sizes. [...]these physicochemical properties affect the residence time, drug release as well as ocular bioavailability of the drug. The recovery trial method was performed at 176 National Health Service organization in the United Kingdom and was supported by the National Institute for Health Research Clinical Research network.
A Brief Review on Ophthalmic Suspension for Covid-19 Infection